Real-life impact of anti-IL5 therapy on exacerbation types in patients with obstructive lung disease.

ABSTRACT:

Background

While anti-interleukin (IL) 5 therapy has been shown to be efficacious to reduce exacerbation rates (ERs) in patients with severe eosinophilic asthma and might also benefit patients with coexisting chronic obstructive pulmonary disease (COPD), it is unknown whether anti-IL5 therapy reduces all types of exacerbations in heterogeneous (smoking) real-life patients.

Methods

Adults initiating mepolizumab or benralizumab between 2017 and 2019 were identified in Belgian nationwide data. The ER in the year before anti-IL5 therapy initiation was compared to the year after. Exacerbations were classified as severe (hospitalised) exacerbations or moderate (outpatient) exacerbations treated with antibiotics, oral corticosteroids (OCS) or the combination.

Results

Among 8

SUBMITTER: Vanfleteren LEGW 

PROVIDER: S-EPMC12551499 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature